A Dark Vector Cognition product

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

45K characters. Original on sec.gov ·

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The 22 tables in Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

ABOUT STRYKER

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes.

We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. MedSurg and Neurotechnology products include surgical equipment and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke (Neurovascular), a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products (Neuro Cranial) and other medical device products used in a variety of medical specialties. Orthopaedics and Spine products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.

COVID-19 Pandemic

The COVID-19 global pandemic has led to severe disruptions in the market and the global and United States economies that may continue for a prolonged duration and trigger a recession or a period of economic slowdown. In response, various governmental authorities and private enterprises have implemented numerous measures to contain the pandemic, such as travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. A significant number of our global suppliers, vendors, distributors and manufacturing facilities are located in regions that have been affected by the pandemic. Those operations have been materially adversely affected by restrictive government and private enterprise measures implemented in response to the pandemic.

Some of our products are particularly sensitive to reductions in elective medical procedures. During the quarter we saw a partial recovery of elective procedures and accelerated sales momentum as the impact of the COVID-19 pandemic has eased in the United States and Europe; however, our sales growth in certain of our products has been constrained by the continuing supply chain challenges and electronic component shortages, especially impacting the capital products in our MedSurg businesses.

Russia and Ukraine Conflict

The military conflict in Russia and Ukraine and the sanctions imposed by the United States government and other nations in response to this conflict have caused significant volatility and disruptions to the global markets. Given that we provide life-saving and life-enhancing products, we plan to continue operating in Russia provided we can safely do so. During the three months 2022 net sales in Russia were approximately 0.1% of our revenues. Although Russia does not constitute a material portion of our business, there is uncertainty around the impact it will have on the global economy, supply chains and fuel prices generally, and therefore our business. Refer to Part II, Item 1A. "Risk Factors" for further details.

China Volume-Based Procurement and Import Purchase Evaluation

The government in China has launched regional and national programs for volume-based procurement ("VBP") of high-value medical consumables to reduce healthcare costs. Each VBP program has specific requirements to award contracts to the lowest bidders who are able to satisfy the quality and quantity requirements. The successful bidders may be guaranteed sales volume for certain products, while unsuccessful bidders may lose unit sales volume. The prices required for a successful bid have negatively impacted our existing commercial operations of joint replacement and trauma products in China. To date our other businesses have not been significantly impacted, but may be in the future. We do not expect any significant impairments related to further VBP programs. China has also issued national guiding standards for Import Purchase Evaluation (IPE) which has increased the purchase of locally sourced equipment in China's public hospitals and is impacting our MedSurg business in China. Our business in China represented approximately 2.5% of our revenues for the three months 2022.

Overview of the Three Months

In the three months 2022 we achieved sales growth of 8.1% from 2021. Excluding the impact of acquisitions and divestitures sales grew 9.2% in constant currency. We reported operating income margin of 10.5%, net earnings of $323 and net earnings per diluted share of $0.84. Excluding the impact of certain items, adjusted operating income margin(1) contracted by 170 basis points to 21.8%, with adjusted net earnings(1) of $752 and adjusted net earnings per diluted share(1) of $1.97 representing growth of 2.1%.

Recent Developments

In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%.

In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. Refer to Note 7 to our Consolidated Financial Statements for further information.

Effective April 1, 2022 our subsidiaries in Turkey will begin accounting for their operations as highly inflationary, as required by United States Generally Accepted Accounting Principles, as the cumulative three year inflation rate in Turkey exceeded 100% in March 2022. We do not expect this change to have a material impact on our Consolidated Financial Statements. During the three months 2022 net sales in Turkey were less than 0.5% of our revenues.

(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-GAAP financial measures used in this report and a reconciliation to the most directly comparable GAAP financial measure.

Dollar amounts are in millions except per share amounts or as otherwise specified.10
STRYKER CORPORATION2022 First Quarter Form 10-Q
CONSOLIDATED RESULTS OF OPERATIONS
Three Months
Percent Net SalesPercentage
2022202120222021Change
Net sales$4,275$3,953100.0%100.0%8.1%
Gross profit2,7342,50964.063.59.0
Research, development and engineering expenses4132889.77.343.4
Selling, general and administrative expenses1,7101,57540.039.88.6
Recall charges1460.30.2nm
Amortization of intangible assets1501813.54.6(17.1)
Other income (expense), net(61)(92)(1.4)(2.3)(33.7)
Income taxes6365nmnm(3.1)
Net earnings$323$3027.6%7.6%7.0%
Net earnings per diluted share$0.84$0.796.3%
Adjusted net earnings per diluted share**(1)**$1.97$1.932.1%

nm - not meaningful

Geographic and Segment Net SalesThree Months
Percentage Change
20222021As ReportedConstant Currency
Geographic:
United States$3,105$2,78411.5%11.5%
International1,1701,1690.16.0
Total$4,275$3,9538.1%9.9%
Segment:
MedSurg and Neurotechnology$2,423$2,19110.6%12.1%
Orthopaedics and Spine1,8521,7625.17.2
Total$4,275$3,9538.1%9.9%
Supplemental Net Sales Growth Information
Three Months
Percentage Change
United StatesInternational
20222021As ReportedConstant CurrencyAs ReportedAs ReportedConstant Currency
MedSurg and Neurotechnology:
Instruments$528$46912.6%14.1%16.6%0.2%6.2%
Endoscopy53846914.816.718.14.812.2
Medical6646226.87.911.0(6.7)(2.4)
Neurovascular3012893.96.5(1.4)7.211.5
Neuro Cranial32328115.116.218.13.58.8
Other696112.312.311.845.746.1
$2,423$2,19110.6%12.1%14.0%1.8%7.0%
Orthopaedics and Spine:
Knees$464$41212.5%14.6%17.5%0.1%7.3%
Hips3273095.98.68.51.98.7
Trauma and Extremities6856407.19.010.6(0.9)5.3
Spine2792780.11.83.7(8.0)(2.5)
Other97123(20.4)(18.9)(23.3)(10.9)(4.2)
$1,852$1,7625.1%7.2%8.2%(1.7)%4.8%
Total$4,275$3,9538.1%9.9%11.5%0.1%6.0%

Consolidated Net Sales

Consolidated net sales increased 8.1% in the three months 2022 as reported and 9.9% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.8%. Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 10.2% from increased unit volume partially offset by 1.0% due to lower prices. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology products and most Orthopaedics and Spine products.

MedSurg and Neurotechnology Net Sales

MedSurg and Neurotechnology net sales increased 10.6% in the three months 2022 as reported and 12.1% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.5%. Excluding the 1.3% impact of acquisitions, net sales in constant currency increased by 10.8% from increased unit volume. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology products.

Orthopaedics and Spine Net Sales

Orthopaedics and Spine net sales increased 5.1% in the three months 2022 as reported and 7.2% in constant currency, as foreign currency exchange rates negatively impacted net sales by

Dollar amounts are in millions except per share amounts or as otherwise specified.11
STRYKER CORPORATION2022 First Quarter Form 10-Q

2.1%. Net sales in constant currency increased 9.5% from increased unit volume partially offset by 2.3% from lower prices. The unit volume increase was due to higher shipments of hips, knees, trauma and extremities and spine products.

Gross Profit

Gross profit as a percentage of sales in the three months 2022 increased to 64.0% from 63.5% in 2021. Excluding the impact of the items noted below, gross profit decreased to 64.1% of sales in the three months 2022 from 65.4% in 2021 due to increased costs from inflationary pressures, primarily related to labor, electronic components, steel and transportation.

Percent Net Sales
Three Months2022202120222021
Reported$2,734$2,50964.0%63.5%
Inventory stepped-up to fair value5790.12.0
Restructuring-related and other charges2(2)—(0.1)
Medical device regulations—1——
Adjusted$2,741$2,58764.1%65.4%

Research, Development and Engineering Expenses

Research, development and engineering expenses increased $125 or 43.4% in the three months 2022 and increased as a percentage of sales to 9.7% from 7.3% in 2021. Excluding the impact of the items noted below, expenses increased to 7.2% of sales in 2022 from 6.8% in 2021.

The increases for the three months are due to disciplined ramp up in spending to facilitate our growth and new product development, investments in new technologies, integration of recent acquisitions and the write-off of certain intangible assets.

Percent Net Sales
Three Months2022202120222021
Reported$413$2889.7%7.3%
Restructuring-related and other charges(79)—(1.8)—
Medical device regulations(28)(18)(0.7)(0.5)
Adjusted$306$2707.2%6.8%

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $135 or 8.6% in the three months 2022 and increased as a percentage of sales to 40.0% from 39.8% in 2021. Excluding the impact of the items noted below, expenses decreased to 35.1% of sales in 2022 from 35.2% in 2021. Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded.

Percent Net Sales
Three Months2022202120222021
Reported$1,710$1,57540.0%39.8%
Other acquisition and integration-related(144)(170)(3.3)(4.2)
Restructuring-related and other charges(28)(15)(0.7)(0.4)
Regulatory and legal matters(37)—(0.9)—
Adjusted$1,501$1,39035.1%35.2%

Recall Charges

Recall charges were $14 in the three months 2022 and $6 in the three months 2021. Charges were primarily due to the previously disclosed Wright hip products. Refer to Note 6 to our Consolidated Financial Statements for further information.

Amortization of Intangible Assets

Amortization of intangible assets was $150 and $181 in the three months 2022 and 2021. Refer to Note 7 to our Consolidated Financial Statements for further information.

Operating Income

Operating income decreased $12 to 10.5% of sales in the three months 2022 from 11.6% of sales in 2021. Excluding the impact of the items noted below, operating income decreased to 21.8% of sales in 2022 from 23.5% in 2021 primarily due to higher costs from inflationary pressures.

Percent Net Sales
Three Months2022202120222021
Reported$447$45910.5%11.6%
Inventory stepped-up to fair value5790.12.0
Other acquisition and integration-related1441703.34.2
Amortization of purchased intangible assets1501813.54.6
Restructuring-related and other charges109142.50.4
Medical device regulations28190.70.5
Recall-related matters1460.30.2
Regulatory and legal matters37—0.9—
Adjusted$934$92821.8%23.5%

Other Income (Expense), Net

Other income (expense), net was ($61) and ($92) in the three months 2022 and 2021. The decrease in net expense in 2022 was primarily due to favorable investment returns, favorable foreign exchange rates, and decreased interest expense driven by the repayment of senior unsecured notes that were due March 15, 2021 and the June 2021 repayment of the term loan due November 2023.

Income Taxes

Our effective tax rates were 16.3% and 17.7% in the three months 2022 and 2021. The change in the effective income tax rate for the three months was primarily due to lower tax expense from our operating structure and current profit mix.

We are routinely audited by income tax authorities in the jurisdictions we operate. It is reasonably possible within the next 12 months that uncertain tax positions, excluding interest, could decrease by as much as $175 as a result of the resolution of tax matters.

Net Earnings

Net earnings increased to $323 or $0.84 per diluted share in the three months 2022 from $302 or $0.79 per diluted share in 2021. Adjusted net earnings per diluted share(1) increased to $1.97 in 2022 from $1.93 in 2021. The impact of foreign currency exchange rates reduced net earnings per diluted share by approximately $0.09 in 2022 and increased net earnings per diluted share by approximately $0.06 in 2021.

Percent Net Sales
Three Months2022202120222021
Reported$323$3027.6%7.6%
Inventory stepped-up to fair value4600.11.5
Other acquisition and integration-related1051292.43.3
Amortization of purchased intangible assets1151512.63.8
Restructuring-related and other charges84181.90.5
Medical device regulations24160.60.4
Recall-related matters1150.30.1
Regulatory and legal matters28—0.7—
Tax matters58561.41.4
Adjusted$752$73717.6%18.6%
Dollar amounts are in millions except per share amounts or as otherwise specified.12
STRYKER CORPORATION2022 First Quarter Form 10-Q

Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted effective income tax rate; adjusted net earnings; adjusted net earnings per diluted share (Diluted EPS); free cash flow; and free cash flow conversion. We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures. To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. To measure free cash flow, we adjust cash provided by operating activities by the amount of purchases of property, plant and equipment and proceeds from long-lived asset disposals and remove the impact of certain legal settlements and recall payments. To measure free cash flow conversion we divide free cash flow by adjusted net earnings. These adjustments are irregular in timing and may not be indicative of our past and future performance. The following are examples of the types of adjustments that may be included in a period:

1.Acquisition and integration-related costs. Costs related to integrating recently acquired businesses (e.g., costs associated with the termination of sales relationships, workforce reductions and other integration-related activities) and specific costs (e.g., inventory step-up and deal costs) related to the consummation of the acquisition process.

2.Amortization of purchased intangible assets. Periodic amortization expense related to purchased intangible assets.

*3.*Restructuring-related and other charges. Costs associated with the termination of sales relationships in certain countries, workforce reductions, elimination of product lines, certain long-lived and intangible asset write-offs and impairments and associated costs and other restructuring-related activities.

*4.*Medical device regulations. Costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the new medical device reporting regulations and other requirements of the European Union and the more stringent regulations for medical devices in China.

*5.*Recall-related matters. Our best estimate of the minimum of the range of probable loss to resolve the Rejuvenate, LFIT V40 and other product recalls.

6.Regulatory and legal matters. Our best estimate of the minimum of the range of probable loss to resolve certain regulatory matters and other legal settlements.

7.Tax matters. Charges represent the impact of accounting for certain significant and discrete tax items.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures at the end of the discussion of Consolidated Results of Operations below. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The weighted-average diluted shares outstanding used in the calculation of non-GAAP net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

Dollar amounts are in millions except per share amounts or as otherwise specified.13
STRYKER CORPORATION2022 First Quarter Form 10-Q
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2022Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetNet EarningsEffective Tax RateDiluted EPS
Reported$2,734$1,710$413$447$(61)$32316.3%$0.84
Reported percent net sales64.0%40.0%9.7%10.5%(1.4)%7.6%
Acquisition and integration-related costs:
Inventory stepped-up to fair value5——5—40.10.01
Other acquisition and integration-related—(144)—144—1054.90.27
Amortization of purchased intangible assets———150—1153.60.30
Restructuring-related and other charges2(28)(79)109—842.50.22
Medical device regulations——(28)28—240.20.06
Recall-related matters———14—110.40.04
Regulatory and legal matters—(37)—37—281.00.08
Tax matters—————58(15.1)0.15
Adjusted$2,741$1,501$306$934$(61)$75213.9%$1.97
Adjusted percent net sales64.1%35.1%7.2%21.8%(1.4)%17.6%
Three Months 2021Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetNet EarningsEffective Tax RateDiluted EPS
Reported$2,509$1,575$288$459$(92)$30217.7%$0.79
Reported percent net sales63.5%39.8%7.3%11.6%(2.3)%7.6%
Acquisition and integration-related costs:
Inventory stepped-up to fair value79——79—602.30.16
Other acquisition and integration-related—(170)—170—1295.10.34
Amortization of purchased intangible assets———181—1512.20.40
Restructuring-related and other charges(2)(15)—1411181.00.05
Medical device regulations1—(18)19—160.30.04
Recall-related matters———6—5(0.5)0.01
Regulatory and legal matters————————
Tax matters—————56(15.1)0.14
Adjusted$2,587$1,390$270$928$(81)$73713.0%$1.93
Adjusted percent net sales65.4%35.2%6.8%23.5%(2.0)%18.6%

FINANCIAL CONDITION AND LIQUIDITY

Three Months20222021
Net cash provided by operating activities$203$452
Net cash used in investing activities(2,682)(96)
Net cash provided by (used in) financing activities993(1,053)
Effect of exchange rate changes on cash and cash equivalents—(8)
Change in cash and cash equivalents$(1,486)$(705)

Operating Activities

Cash provided by operating activities was $203 and $452 in the three months 2022 and 2021. The decrease was primarily due to changes in working capital.

Investing Activities

Cash used in investing activities was $2,682 and $96 in the three months 2022 and 2021. The increase in cash used in 2022 was primarily due to increased payments for acquisitions.

Financing Activities

Cash provided by (used in) financing activities was $993 and ($1,053) in the three months 2022 and 2021. Cash provided in 2022 was primarily driven by the issuance of a $1,500 term loan used to fund the Vocera acquisition and the issuance of commercial paper, partially offset by the payment of dividends. Cash used by financing activities in the three months 2021 was primarily due to debt repayments of $750 in March 2021. We did not repurchase any shares in the three months 2022 or 2021.

Three Months20222021
Total dividends paid to common shareholders$262$238

Liquidity

Cash, cash equivalents and marketable securities were $1,530 and $3,019 on March 31, 2022 and December 31, 2021. Current

assets exceeded current liabilities by $4,317 and $5,468 on March 31, 2022 and December 31, 2021. We anticipate being able to support our short-term liquidity and operating needs from a variety of sources including cash from operations, commercial paper and existing credit lines.

We raised funds in the capital markets in the past and may continue to do so from time-to-time. We continue to have strong investment-grade short-term and long-term debt ratings that we believe should enable us to refinance our debt as needed.

Our cash, cash equivalents and marketable securities held in locations outside the United States was approximately 44% on March 31, 2022 compared to 26% on December 31, 2021.

Critical Accounting Policies

There were no changes to our critical accounting policies from those disclosed in our Annual Report on Form 10-K for 2021.

New Accounting Pronouncements Not Yet Adopted

Refer to Note 1 to our Consolidated Financial Statements for information.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, of a magnitude that we believe could have a material impact on our financial condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of our business, including proceedings related to product, labor, intellectual property and

Dollar amounts are in millions except per share amounts or as otherwise specified.14
STRYKER CORPORATION2022 First Quarter Form 10-Q

other matters. Refer to Note 6 to our Consolidated Financial Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements referring to us that are not historical facts and are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which are intended to take advantage of the "safe harbor" provisions of the Reform Act, are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include words such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project," "intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict, including uncertainties related to the impact of the COVID-19 pandemic on our operations and financial results. Therefore, actual results could differ materially and adversely from these forward-looking statements. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include those risks discussed in Item 1A. "Risk Factors" of our Annual Report on Form 10-K for 2021. This Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes to our Consolidated Financial Statements in our Annual Report on Form 10-K for 2021. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Previous: Item 1. FINANCIAL STATEMENTS · Next: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK